Medifocus Inc. (OTCPK:MDFZ.F) announced a non brokered private placement of 6,666,666 units at CAD 0.15 per unit for gross proceeds of CAD 1,000,000 on November 30, 2012. Each unit is comprised of one common share and one series D common share purchase warrant. Each series D common share purchase warrant will entitle the holder to purchase one additional common share at a price of CAD 0.20 for a period of 24 months following the closing of the transaction. If, at any time prior to the warrants expiration date, the daily volume weighted average trading price of the common shares on the TSX Venture Exchange exceeds CAD 0.75 for at least 10 consecutive trading days, the company may, within 30 days of such occurrence, give an expiry acceleration notice to the holders of warrants and, if it does so, the warrants will, unless exercised, expire on the 30th day after the expiry acceleration notice is given.

On December 11, 2012, the company amended the terms of the transaction. The company will now issue 13,333,333 units for CAD 2,000,000. The company may pay finders' fee of 7% of gross proceeds raised in the transaction. The securities to be issued in the transaction are subject to a hold period of four months and one day from the date of issuance.

On January 14, 2013, Medifocus Inc. closed the transaction. The company issued 13,056,997 units for gross proceeds of CAD 1,958,549.55. The securities were issued to 28 placees. The securities are subject to a hold period expiring May 15, 2013. The company paid a 7% finder's fee on CAD 7,500 of CAD 525 to Canaccord Genuity Corp.